About US
Contact us
-
Moderna's new CFO out the door after former employer discloses accounting probeThat was fast. Just a month after mRNA giant Moderna unveiled a CFO switch, its new finance chief is out the door because his former employer disclosed an internal accounting probe. Moderna's C2022/5/12
-
After 2 years, Sanofi's drug ingredients spinoff takes flightIt’s official: Two years and one pandemic after Sanofi unveiled plans to spin off its European drug ingredients business, EUROAPI has debuted on the Euronext exchange. Shares in the new active pharma2022/5/10
-
Enhertu's breast cancer nod; Biogen, Eisai's next play; FDA snubs 2 China-made cancer drugsWith a new FDA approval for Enhertu, AstraZeneca and Daiichi Sankyo are heaping pressure on Roche and Seagen. As Biogen terminates its Aduhelm marketing efforts, the focus has shifted to its second A2022/5/10
-
Marinus restarts phase 3 seizure trials after stability, COVID delaysMarinus Pharmaceuticals isrestartingits phase 3 seizure clinical trials that had been delayed by clinical supply disruptions and the COVID-19 pandemic. The company has r2022/5/6
-
Thermo Fisher, Charles River join robotics outfit Multiply Labs' quest to automate cell therapy productionOn a quest to automate manual portions of the cell therapy production process, Multiply Labs is arming itself with two more pieces of industry-leading tech. The new kit comes on board a little less t2022/5/6
-
Pfizer and BioNTech seek FDA EUA for Covid-19 booster in childrenPfizer and BioNTech have submitted anapplicationseeking Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a 10µg booster dose of their Covid-19 vaccine in children2022/4/28
-
Cytovia signs business combination agreement with IsleworthCytovia has signed a definitive business combinationagreementwith special purpose acquisition company (SPAC) Isleworth Healthcare Acquisition to create a publicly listed company focusing on natural k2022/4/28
-
Is AstraZeneca finally ready to score with underachieving cancer drug tremelimumab?After years of failing to live up to expectations in a variety of cancer types, is AstraZeneca’s tremelimumab staging a better-late-than-never rally? Less than a year ag2022/4/26
-
COVID-19 tracker: US government will make Pfizer's Paxlovid available at all pharmaciesUnder a Biden administration plan, Pfizer's Paxlovid will soon be available at all U.S. pharmacies. The White House COVID-19 response coordinator says hospitalizations a2022/4/26
-
COVID-19 tracker: UK study finds strong responses 84 days after booster shotA U.K. study documented strong immune responses from various booster vaccines. CureVac and GlaxoSmithKline announced positive preclinical data for their new variant-specificmRNA vaccine candida2022/4/22